Several newly identified genetic variants on chromosome 8 are associated with increased risk of developing prostate cancer, according to three studies to be published online this week in Nature Genetics.
Scientists with the Lineberger Comprehensive Cancer Center at the University of North Carolina at Chapel Hill have for the first time implicated a growth-promoting cellular protein as one trigger of the inevitable recurrence of advanced prostate cancer in men who are undergoing drug treatment to shut down their sex hormones, or androgens.
MRI and MRS can provide a roadmap of the prostate and assist in surgical planning of robotically assisted laparoscopic radical prostatectomy, according to a recent study conducted by researchers at the University of California, Los Angeles.
The unique application of operations research to the treatment of prostate cancer allowed Memorial Sloan-Kettering Cancer Center to better Fortune 500 companies last night and win an international competition for best project by an organization.
In a study published in the April issue of the journal Urology, Getzenberg and a team of Hopkins researchers introduce evidence in support of EPCA-2 testing as a more accurate way to identify cancer in the prostate.
A rigorous, long-term study of quality of life in patients who underwent one of three common prostate cancer treatments found that each treatment affected men’s lives in different ways.
New studies of a blood protein recently identified at Johns Hopkins, early prostate cancer antigen-2 (EPCA-2), may change the way men are screened for prostate cancer – a disease that kills tens of thousands of men every year.
In the February 2007 issue of Urology, Dr. Ellis from the Urology Associates of North Texas reports on a large series of patients treated with primary cryotherapy for prostate cancer (CaP).
A research team at Columbia University has designed a novel viral-based gene therapy they say blasts through a body, targeting both primary and distant tumors, while leaving normal cells untouched.
Selenium may offer an intervention strategy for the treatment of prostate cancer according to results of a study from the laboratory of Allen Gao, PhD, which will be presented by Yan Hu, PhD, Departments of Medicine and Pharmacology and Therapeutics, Roswell Park Cancer Institute (RPCI) at the 2007 centennial meeting of the American Association for Cancer Research (AACR), April 14-18, in Los Angeles, CA.